NCT04080544View on ClinicalTrials.gov

Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Alzheimer DiseaseCognitive Decline
Interventions
DRUG

[18F]AV-1451

The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.

PROCEDURE

Positron Emission Tomography

Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

Neil M Rofsky, MD, MHA

OTHER

NCT04080544 - Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study | Biotech Hunter | Biotech Hunter